共查询到20条相似文献,搜索用时 15 毫秒
1.
Making the most of mucin: a novel target for tumor immunotherapy 总被引:4,自引:0,他引:4
Simon M. Barratt-Boyes 《Cancer immunology, immunotherapy : CII》1996,43(3):142-151
2.
Anti-idiotype cancer vaccines: past and future 总被引:2,自引:0,他引:2
D. Herlyn Rajasekharan Somasundaram Weiping Li Haruhiko Maruyama 《Cancer immunology, immunotherapy : CII》1996,43(2):65-76
Anti-idiotypic antibodies (Ab2) binding to the antigen-combining site of antitumor antibodies (Ab1) can induce anti-anti-idiotypic
antibodies (Ab3) that specifically bind to the tumor antigen recognized by Ab1. Furthermore, Ab2, mimicking tumor antigens,
have been shown to induce anti-anti-idiotypic proliferative T lymphocytes of the helper and suppressor type, as well as cytotoxic
lymphocytes. The immunomodulatory activities of Ab2 have been demonstrated both in animals and in patients. The demonstration
of tumor growth inhibition by anti-idiotypes in preclinical and phase I clinical studies emphasizes that randomized control
trials should be performed to demonstrate clinical efficacy of Ab2 vaccines.
Received: 25 July 1996 / Accepted: 22 August 1996 相似文献
3.
Oncogene products represent potential targets of tumor vaccines 总被引:1,自引:0,他引:1
T. M. Tuttle 《Cancer immunology, immunotherapy : CII》1996,43(3):135-141
4.
Carcinoembryonic antigen as a target for cancer vaccines 总被引:2,自引:0,他引:2
5.
Shigenori Goto Sumitaka Sakai Jiro Kera Yukie Suma Gen-Ichiro Soma Shoshichi Takeuchi 《Cancer immunology, immunotherapy : CII》1996,42(4):255-261
Lipopolysaccharide (LPS) has been recognized as a potent antitumor agent in animal tumor models; however, its use in human
cancer therapy has been limited to only one trial, in which LPS from Salmonella was given intravenously. It was not very successful because of poor tumor response and was also toxic. We originally developed
LPS prepared from Pantoea agglomerans (LPSp), and this was a well-purified, small-molecular-mass (5 kDa) agent. We chose intradermal rather than intravenous administration
in the hope that the former would release LPS slowly into the bloodstream, and thus be less toxic while preserving antitumor
activity. In our animal tumor models, intradermal administration was indeed less toxic and more beneficial for tumor regression
than intravenous administration. We made a pilot study with intradermal administration of LPSp on the treatment of ten advanced
cancer patients. Five of them had evaluable tumor, which had failed earlier to respond to conventional chemotherapy. Cyclophosphamide
was also administered in this trial, in anticipation of its synergistic effect with LPSp. In this study LPSp was injected
intradermally into each patient twice a week, starting with an initial dose of 0.4 ng/kg, and raising it to 600 or 1800 ng/kg.
A 400-mg/m2 dose of cyclophosphamide was given intravenously every 2 weeks. After completion of the dose escalation, the treatment was
continued for at least 4 months, and it was found that 1800 ng/kg LPSp was well tolerated. A significant level of cytokines
was observed in the sera for at least 8 h. These results indicate higher tolerable doses and remarkably more continuous induction
of the cytokines than were reported in a previous study by others using intravenous administration. Three of the five evaluable
tumors showed a significant response to our combined therapy. Intradermally administered, LPS was less toxic and elicited
a tumor response in combination with cyclophosphamide; it can thus can be applied to cancer treatment even in humans.
Received: 3 August 1995 / Accepted: 2 April 1996 相似文献
6.
Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma 总被引:8,自引:0,他引:8
Kobayashi T Yamanaka R Homma J Tsuchiya N Yajima N Yoshida S Tanaka R 《Cancer immunology, immunotherapy : CII》2003,52(10):632-637
In this study, we demonstrate that tumor mRNA–loaded dendritic cells can elicit a specific CD8+ cytotoxic T-lymphocyte (CTL) response against autologous tumor cells in patients with malignant glioma. CTLs from three patients expressed strong cytolytic activity against autologous glioma cells, did not lyse autologous lymphoblasts or EBV-transformed cell lines, and were variably cytotoxic against the NK-sensitive cell line K-562. Also, DCs-pulsed normal brain mRNA failed to induce cytolytic activity against autologous glioma cells, suggesting the lack of autoimmune response. Two patients' CD8+ T cells expressed a modest cytotoxicity against autologous glioma cells. CD8+ T cells isolated during these ineffective primings secreted large amounts of IL-10 and smaller amounts of IFN- as detected by ELISA. Type 2 bias in the CD8+ T-cell response accounts for the lack of cytotoxic effector function from these patients. Cytotoxicity against autologous glioma cells could be significantly inhibited by anti-HLA class I antibody. These data demonstrate that tumor mRNA–loaded DC can be an effective tool in inducing glioma-specific CD8+ CTLs able to kill autologous glioma cells in vitro. However, high levels of tumor-specific tolerance in some patients may account for a significant barrier to therapeutic vaccination. These results may have important implications for the treatment of malignant glioma patients with immunotherapy. DCs transfected with total tumor RNA may represent a method for inducing immune responses against the entire repertoire of glioma antigens. 相似文献
7.
N. Mador Haya Falk Michael Bergel Amos Panet J. Hochman 《Cancer immunology, immunotherapy : CII》1997,44(5):249-256
We have previously developed an experimental model for the xenogenization of malignant lymphoma. From highly tumorigenic
S49 mouse lymphoma cells that proliferate in suspension culture (designated T-25), we selected variant clones that grew as
an adherent monolayer (designated T-25-Adh) and were non-tumorigenic in syngeneic mice. Furthermore, priming of syngeneic
hosts with T-25-Adh cells protected them against subsequent challenges with the tumorigenic T-25 cells. Several lines of evidence
have indicated that antigens of an endogenous mouse mammary tumor virus (MMTV) are involved in the immunogenicity of T-25-Adh
cells. Since interferon (IFN) is known to affect retroviral assembly and maturation on the cell membrane, we have studied
the effects of IFN on endogenous MMTV-related structures, as well as on the immunogenicity of T-25-Adh cells. We observed
that mouse α and β interferons affect the morphogenesis of intracellular MMTV-related precursors in the immunogenic T-25-Adh
cells, but not in tumorigenic T-25 cells. From T-25-Adh cells we selected variants that were either high responders or low
responders to the above-mentioned interferon effect. The high-response variants were significantly more protective against
tumorigenic T-25 cells than the low-response variants. Involvement of MMTV-related antigens in the immune response of the
host to T-25-Adh cells was further suggested by immunoelectron-microscopical analysis, demonstrating that antisera from mice,
immunized with T-25-Adh cells, interacted specifically with cell-surface MMTV budding particles. These findings indicate a
novel method for xenogenization of lymphoma cells by IFN. Since endogenous retroviruses are present in all tissues of the
mouse, this approach might be applicable to a wide variety of tumors.
Received: 6 June 1995 / Accepted: 13 March 1997 相似文献
8.
Weisong Xu Edwin de Zoeten Victoria Carr-Brendel E. P. Cohen 《Cancer immunology, immunotherapy : CII》1997,45(5):217-224
Tumor-associated T cell epitopes are recognized by T cells in the context of determinants specified by class I loci. Since
the rejection of foreign histocompatibility antigens is known to enhance tumor immunity, immunization with a cellular vaccine
that combined the expression of both syngeneic and allogeneic class I determinants could have important immunological advantages
over a vaccine that expressed either syngeneic or allogeneic determinants alone. To investigate this question in a mouse melanoma
model system, we tested the immunotherapeutic properties of B16 melanoma × LM fibroblast hybrid cells in C57BL/6J mice with
melanoma. Like C57BL/6J mice, B16 cells expressed H-2Kb class I determinants and (antibody-defined) melanoma-associated antigens. LM cells, of C3H mouse origin, formed H-2Kk determinants along with B7.1, a co-stimulatory molecule that can activate T cells. The B16 × LM hybrid cells co-expressed
H-2Kb and H-2Kk class I determinants, B7.1 and the melanoma-associated antigens. C57BL/6J mice with melanoma, immunized with the semi-allogeneic
hybrid cells, developed CD8-mediated melanoma immunity and survived significantly (P<0.005) longer than mice with melanoma
immunized with a mixture of the parental cell types. The failure of melanoma immunity to develop in mice injected with the
mixture of parental cells indicated that co-expression of the immunogenic determinants by the same cellular immunogen was
necessary for an optimum immunotherapeutic effect. Augmented immunity to melanoma in mice immunized with the semi-allogeneic
hybrid cells points toward an analogous form of therapy for patients with melanoma.
Received: 19 May 1997 / Accepted: 23 July 1997 相似文献
9.
N. J. Meropol Grace M. Barresi Todd A. Fehniger James Hitt Margaret Franklin Michael A. Caligiuri 《Cancer immunology, immunotherapy : CII》1998,46(6):318-326
Natural killer (NK) cells may be expanded in vivo with a prolonged course of daily subcutaneous interleukin-2 (IL-2). However,
cellular activation requires higher concentrations of IL-2 than are achieved with low-dose therapy. The objective of the current
trial was to determine the toxicity and immunological effects of periodic subcutaneous intermediate-dose IL-2 pulses in patients
receiving daily low-dose therapy. A group of 19 patients were treated with daily subcutaneous low-dose IL-2 at 1.25×106 International Units (1.25 MIU) m–2 day–1. After 4–6 weeks, patients received escalating 3-day intermediate-dose IL-2 pulses administered as single daily subcutaneous
injections, repeated at 2-week intervals. The maximum tolerated pulse dose was 15 MIU m–2 day–1, with transient hypotension, fatigue, and nausea/vomiting dose-limiting. Subcutaneous IL-2 resulted in in vivo expansion
of CD56+ NK cells (796±210%) and CD56bright natural killer (NK) cells (3247±1382%). Expanded NK cells coexpressed CD16, and showed lymphokine-activated killer activity
and antibody-dependent cellular cytotoxicity in vitro. Intermediate-dose pulsing resulted in serum IL-2 concentrations above
100 pM. Cellular activation was suggested by rapid margination of NK cells following pulsing, coincident with peak IL-2 levels,
with return to baseline by 24 h. In addition, interferon γ production in response to lipopolysaccharide was augmented. Subcutaneous
daily low-dose IL-2 with intermediate-dose pulsing is a well-tolerated outpatient regimen that results in in vivo expansion
and potential activation of NK cells, with possible application in the treatment of malignancy and immunodeficiency.
Received: 31 December 1997 / Accepted: 20 April 1998 相似文献
10.
Dendritic cells presenting tumor antigen 总被引:13,自引:0,他引:13
Michael R. Shurin 《Cancer immunology, immunotherapy : CII》1996,43(3):158-164
Since the first identification of dendritic cells by Steinman and Cohn in 1973, progress in understanding their biology has
included the development of novel methods of cell culture, recognition of critical aspects of migration and maturation, and
appreciation of their major role as antigen-presenting cells (APC), and how this activity is regulated by cytokines and expression
of accessory molecules. Dendritic cells are the major APC involved in the initiation of the immune response and the development
of tolerance. There is considerable evidence that they can acquire antigen in the peripheral tissues and process, transport,
and present it to T cells in secondary lymphoid tissue. A number of studies show that, in vitro or in vivo, antigen-pulsed
dendritic cells can directly sensitize T cells and stimulate the development of antigen-specific immune responses, including
both protective and therapeutic antitumor responses. In this paper, several important aspects of dendritic cell biology are
discussed and a number of studies confirming the role of these professional APC in antitumor immunity are reviewed.
Received: 6 August 1996 / Accepted: 20 September 1996 相似文献
11.
目的:探讨树突状细胞(DCs)和细胞因子诱导的杀伤(CIK)细胞免疫治疗联合化疗对晚期非小细胞肺癌患者的治疗效果。方法:将我院2012年2月到2014年2月就诊的72例晚期非小细胞肺癌患者随机分为对照组(n=36,单纯化疗组)和实验组(n=36,DCs-CIK细胞免疫联合化疗组)。比较两组患者治疗后的疗效、治疗前后免疫功能,并运用Kamofsky(KPS)评分来评估两组患者治疗后生活质量的改善情况。结果:实验组的疾病控制率(DCR)77.78%显著高于对照组的52.78%(P0.05)。治疗后实验组患者外周血CD3+、CD8+及NK细胞所占的比值较治疗前均上升显著(P0.05);治疗后对照组患者外周血CD3+、CD8+及NK细胞所占的比值较治疗前下降显著(P0.05)。治疗后实验组KPS评分提高率明显高于对照组(P0.05)。结论:DCs-CIK细胞免疫联合化疗能够提高晚期非小细胞肺癌患者的DCR,且显著改善患者的免疫功能和生活质量。 相似文献
12.
Carrasco-Marín E Rodriguez-Del Rio E Frande-Cabanes E Tobes R Pareja E Lecea-Cuello MJ Ruiz-Sáez M Madrazo-Toca F Hölscher C Alvarez-Dominguez C 《The Journal of biological chemistry》2012,287(18):14310-14324
Phagosomes are critical compartments for innate immunity. However, their role in the protection against murine listeriosis has not been examined. We describe here that listericidal phago-receptosomes are induced by the function of IFN-γ or IL-6 as centralized compartments for innate and adaptive immunity because they are able to confer protection against murine listeriosis. These phago-receptosomes elicited LLO(91-99)/CD8(+)- and LLO(189-201)/CD4(+)-specific immune responses and recruited mature dendritic cells to the vaccination sites controlled by T cells. Moreover, they present exceptional features as efficient vaccine vectors. First, they compartmentalize a novel listericidal STAT-1-mediated signaling pathway that confines multiple innate immune components to the same environment. Second, they show features of MHC class II antigen-loading competent compartments for cathepsin-D-mediated LLO processing. Third, murine cathepsin-D deficiencies fail to develop protective immunity after vaccination with listericidal phago-receptosomes induced by IFN-γ or IL-6. Therefore, it appears that the connection of STAT-1 and cathepsin-D in a single compartment is relevant for protection against listeriosis. 相似文献
13.
C. A. Savary Monica L. Grazziutti Bohuslav Melichar Donna Przepiorka Ralph S. Freedman Richard E. Cowart D. M. Cohen E. J. Anaissie Darren G. Woodside Bradley W. McIntyre Duane L. Pierson Neal R. Pellis John H. Rex 《Cancer immunology, immunotherapy : CII》1997,45(5):234-240
We studied the potential of multidimensional flow cytometry to evaluate the frequency and maturation/activation status of
dendritic cells in minimally manipulated peripheral blood mononuclear cell preparations (i.e., only separated on Ficoll-Hypaque)
of normal donors and cancer patients. A rare subset of HLA-DR+ leukocytes (less than 1% mononuclear cells) was detected in blood of normal donors that displayed all the features of dendritic
cells: these cells had high forward-light-scatter characteristics and coexpressed CD4, CD86 and CD54 surface antigens, but
lacked the lineage-associated surface markers of T cells, B cells, monocytes, granulocytes or NK i.e. they were CD3–, CD19–, CD20–, CD14–, CD11b–, CD16–, CD56–). These physical and phenotypic properties were virtually identical to those of immunomagnetically sorted leukocytes characterized
as dendritic-cells on the basis of morphology, phenotype and high stimulatory activity in allogeneic mixed-lymphocyte cultures.
Using this flow-cytometric approach we observed that the frequency of dendritic cell-like cells in peripheral blood mononuclear
cell specimens of cancer patients receiving chemotherapy alone or those recovering from stem cell transplantation was significantly
lower than that of normal individuals (mean ± SE: 0.36 ± 0.05%, 0.14 ± 0.06%, and 0.75 ± 0.04% respectively). Multidimensional
flow-cytometric analysis of dendritic cells might represent an important new tool for assessing immunocompetence, and for
monitoring the effects of therapeutic regimens on the immune system.
Received: 20 June 1997 / Accepted: 14 August 1997 相似文献
14.
Koji Tamada M. Harada Koichiro Abe Tieli Li Hitoshi Tada Yasuhiro Onoe Kikuo Nomoto 《Cancer immunology, immunotherapy : CII》1998,46(3):128-136
In order to enhance the antitumor vaccination effect of dendritic cells (DC) pulsed with class I tumor peptide, we tried
to utilize the local cytokine help of CD4+ T cells reactive to a streptococcal preparation OK432. DC were prepared from murine bone marrow cells by culture with both
granulocyte/macrophage-colony-stimulating factor and interleukin(IL)-4. The peritumoral injections of OK432 induced OK432-reactive
CD4+ T cells in the draining lymph nodes, and their in vitro production of interferon γ was thus significantly enhanced by restimulation
with OK432-pulsed DC. In addition, anti-P815 mastocytoma cytotoxic T lymphocytes were generated from the in vivo OK432-treated
P815-draining lymph node cells only when the lymph node cells were restimulated in vitro with the DC pulsed with both P1A
peptide and OK432. Moreover, the peritumoral injections of OK432 and the subsequent vaccination of the DC, pulsed with both
OK432 and P1A peptide, significantly suppressed the growth of s.c. inoculated P815. Interestingly, a significant level of
IL-12 was detected in the coculture supernatant of both OK432-pulsed DC and OK432-reactive CD4+ T cells. Collectively, our results suggest that the antitumor vaccination effect of DC pulsed with class I tumor peptide
could thus be effectively augmented by locally utilizing the Th1-type cytokines from OK432-reactive CD4+ T cells.
Received: 18 July 1997 / Accepted: 23 December 1997 相似文献
15.
16.
Koichiro Abe Mamoru Harada Koji Tamada Osamu Ito Tieli Li Kikuo Nomoto 《Cancer immunology, immunotherapy : CII》1997,45(5):225-233
Both natural killer (NK) cells and macrophages are thought to be the main effectors responsible for early antitumor defense.
In this study, we investigated the role of tumor-infiltrating NK cells in initiating nitric oxide (NO) production by tumor-associated
macrophages (TAM). The in vivo depletion of NK cells prior to the i.p. inoculation of melanoma cells resulted in a significant
decrease in the NO production of the TAM prepared from the peritoneal exudate cells (PEC). Such prior NK cell depletion also
decreased the ability of TAM to show any antitumor activity in vitro. The addition of N
G-monomethyl-L-arginine (Me-L-Arg) to the culture partially inhibited the ability of TAM to suppress the proliferation of melanoma cells and also decreased
their cytolytic activity against melanoma cells. These results suggest that the TAM exhibited both cytostatic and cytolytic
activities through their NO production. In an in vivo assay, the administration of Me-L-Arg permitted the more rapid growth of i.p. inoculated melanoma cells compared with the control. On the other hand, the decreased
NO production of TAM, resulting from the prior NK cell depletion, was restored by the i.p. administration of interferon γ
(IFNγ). In addition, the in vivo administration of anti-IFNγ mAb into mice inoculated i.p. with melanoma cells also significantly
decreased the NO production of TAM in peritoneal exudate cells. Furthermore, the tumor-infiltrating NK cells produced a considerable
level of IFNγ. Overall, these results indicate that early-appearing tumor-infiltrating NK cells play an important role in
the NO production of TAM through their IFNγ production.
Received: 11 March 1997 / Accepted: 31 July 1997 相似文献
17.
A. Eisenthal Yechiel Goldman Yehuda Skornick Anna Gelfand Diana Buyaner Issac Kaver Alon Yellin Henry Yehoshua Beatriz Lifschitz-Mercer Amnon Gonnene M. Shinitzky 《Cancer immunology, immunotherapy : CII》1998,46(6):304-310
Hydrostatic pressure (P) combined with membrane protein crosslinking (CL) by adenosine dialdehyde (AdA) can render tumor
cells immunogenic. We have recently shown that PCL treatment of murine tumor cells augmented the presentation of MHC-restricted
tumor-associated antigens and enhanced cell-mediated immunity. In cancer patients inoculated with autologous PCL-modified
tumor cells, a significant delayed-type hypersensitivity response was elicited. Since the balance between cell-mediated immunity
and humoral immunity is reciprocally controlled by immunoregulatory cytokines, we have examined the proliferative response
and cytokine secretion pattern in cultures of human peripheral blood mononuclear cells (PBMC) stimulated by autologous PCL-modified
and unmodified tumor cells. These tumor cells were obtained from freshly resected tumor tissue of 16 patients with colon (8),
lung (4) and renal (4) carcinomas. The results demonstrated that PCL-modified tumor cells promoted an increase in PBMC proliferation
in 5 out of 8 (63%), 1 out of 4 (25%) and 4 out of 4 (100%) colon, lung and renal cell carcinomas. Fourteen of the above cultures
were also analyzed for the secretion of interleukin-10 and interferon-γ. Overall, a substantial decrease in IL-10 secretion
was detected in 9 out of 14 (64%) cultures while a reciprocal increase in interferon-γ secretion was noted in 8 out of 14
(57%) cultures. Our results confirmed that PCL-modified human tumor cells of different etiologies can modulate the pattern
of cytokines released from stimulated autologous lymphocytes. Such a procedure could prove valuable in the production of autologous
tumor vaccines.
Received: 8 January 1998 / Accepted: 9 April 1998 相似文献
18.
Adam S. Giermasz Julie A. Urban Yutaro Nakamura Payal Watchmaker Rachel L. Cumberland William Gooding Pawel Kalinski 《Cancer immunology, immunotherapy : CII》2009,58(8):1329-1336
While multiple pathways of dendritic cell (DC) maturation result in transient production of IL-12, fully mature DCs show reduced
ability to produce IL-12p70 upon a subsequent interaction with Ag-specific T cells, limiting their in vivo performance as
vaccines. Such “DC exhaustion” can be prevented by the presence of IFNγ during the maturation of human DCs (type-1-polarization),
resulting in improved induction of tumor-specific Th1 and CTL responses in vitro. Here, we show that type-1 polarization of
mouse DCs strongly enhances their ability to induce CTL responses against a model tumor antigen, OVA, in vivo, promoting the
induction of protective immunity against OVA-expressing EG7 lymphoma. Interestingly, in contrast to the human system, the
induction of mouse DC1s requires the participation of IL-4, a nominal Th2-inducing cytokine. The current data help to explain
the previously reported Th1-driving and anti-tumor activities of IL-4, and demonstrate that type-1 polarization increases
in vivo activity of DC-based vaccines.
Electronic supplementary material The online version of this article (doi:) contains supplementary material, which is available to authorized users.
Adam S. Giermasz and Julie A. Urban contributed equally to this work. 相似文献
19.
The generation of anti-tumoral cells using dentritic cells from the peripheral bloood of patients with malignant brain tumors 总被引:3,自引:0,他引:3
Yoshida S Morii K Watanabe M Saito T Yamamoto K Tanaka R 《Cancer immunology, immunotherapy : CII》2001,50(6):321-327
Dendritic cells (DCs) can be the principal initiators of antigen-specific immune responses. We analyzed the in vitro-responses
against brain tumor cells using DCs from the peripheral blood of patients with brain tumors. Peripheral blood mononuclear
cells (PBMC) were obtained from 19 patients with malignant brain tumors: 12 metastatic brain tumors of lung adenocarcinoma,
7 high-grade astrocytomas. PBMC were cultured with 100 ng/ml of GM-CSF and 10 ng/ml of IL-4 for 5–7 days in order to produce
mature DCs. The autologous tumor lysate (5 mg/ml, containing 1 × 106 cells) was then added to the cultured DCs. Using the DCs generated by these treatments, we assessed the changes that occurred
in their immune responses against brain tumor via 51Cr-release and lymphocyte proliferation assays. We found that the matured DCs displayed the typical surface phenotype of CD3+, CD45+, CD80+ and CD86+. After the pulsation treatment with tumor lysate, DCs were found to have strong cytotoxic T lymphocyte activity, showing
42.5 ± 12.7% killing of autologous tumor cells. We also found an enhancement of allogeneic T cell proliferation after pulsing
the DC with tumor lysate. These data support the efficacy of DC-based immunotherapy for patients with malignant brain tumors.
Received: 2 October 2000 / Accepted: 26 April 2001 相似文献
20.
Da-Yong Cao Jing-Yue Yang Shu-Qiang Yue Zhen-Shun Song Yan-Ling Yang 《Cellular immunology》2009,259(1):13-20
Fusions of patient-derived dendritic cells (DCs) and autologous tumor cells induce T-cell responses against autologous tumors in animal models and human clinical trials. These fusion cells require patient-derived tumor cells, which are not, however, always available. Here we fused autologous DCs from patients with hepatocellular carcinoma (HCC) to an allogeneic HCC cell line (HepG2). These fusion cells co-expressed tumor-associated antigens (TAAs) and DC-derived costimulatory and MHC molecules. Both CD4+ and CD8+ T cells were activated by the fusion cells. Cytotoxic T lymphocytes (CTLs) induced by the fusion cells were able to kill autologous HCC by HLA-A2- and/or HLA-A24-restricted mechanisms. CTL activity against shared TAAs indicates that the presence of alloantigens does not prevent the development of CTLs with activity against autologous HCC cells. These fusion cells may have applications in anti-tumor immunotherapy through cross-priming against shared tumor antigens and may provide a platform for adoptive immunotherapy. 相似文献